Abstract: FR-PO586
Antisense Oligonucleotide Knock Down of Uromodulin: A Potential Treatment Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)
Session Information
- Genetic Diseases: Tubulopathies
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1202 Genetic Diseases of the Kidneys: Non-Cystic
Authors
- Morgan, Kathy Ye, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Jungels, Nino, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Jinadasa, Tushare, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Greer, Christopher, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Garcia, Stephanie, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Tan, Xuyu, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Adhikari, Kailash, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Guerlavais, Vincent, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Kim, Kevin, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Oliver, Ryan A., Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
- Malmberg, Annika, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
Background
Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin (ADTKD-UMOD) is a genetic disease caused by destabilizing mutations in the uromodulin (UMOD) or Tamm-Horsfall protein. Misfolded UMOD protein aggregates and accumulates inside the loop of Henle and the distal convoluted tubule, leading to progressive and irreversible chronic kidney disease. We hypothesized that peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) could knock down UMOD expression and potentially reduce the disease-causing UMOD aggregation inside the cells.
Methods
A library of PPMOs was designed to bind to the complementary sequences of the mouse Umod gene and induce nonsense-mediated decay. These PPMOs were screened in mIMCD-3 cells, which express endogenous transcript to identify the most active compounds. The most efficacious PPMO compound was tested in both wildtype and UMOD C93F mice, a well characterized disease model of ATDKD, to determine the ability of the PPMO to reduce UMOD expression at the transcript and protein levels.
Results
A single dose of lead PPMO resulted in a 70% knockdown of Umod transcript that led to protein reduction that was sustained for at least 28 days. Furthermore, UMOD protein expression was reduced in the UMOD C93F animals after a single dose of PPMO.
Conclusion
This study shows the ability of PPMO technology to reduce UMOD transcript and protein levels in vitro and in vivo.
Funding
- Commercial Support – Sarepta